Vor Biopharma Inc [VOR] stock prices are down -3.94% to $16.59 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The VOR shares have gain 17.99% over the last week, with a monthly amount glided 21.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vor Biopharma Inc [NASDAQ: VOR] stock has seen the most recent analyst activity on January 09, 2026, when Citigroup initiated its Buy rating and assigned the stock a price target of $50. On December 09, 2025, JP Morgan initiated with a Overweight rating and assigned a price target of $43 on the stock. Robert W. Baird upgraded its rating to a Outperform but $64 remained the price target by the analyst firm on October 15, 2025. Stifel upgraded its rating to Buy for this stock on September 24, 2025, but kept the price target unchanged to $55. In a note dated June 30, 2025, H.C. Wainwright upgraded an Buy rating on this stock but restated the target price of $3.
The stock price of Vor Biopharma Inc [VOR] has been fluctuating between $2.62 and $65.80 over the past year. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. Vor Biopharma Inc [NASDAQ: VOR] shares were valued at $16.59 at the most recent close of the market. An investor can expect a potential return of 213.44% based on the average VOR price forecast.
Analyzing the VOR fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -13.9, Equity is 2.75 and Total Capital is -2.33. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Vor Biopharma Inc [NASDAQ:VOR]’s Current Ratio is 9.16. As well, the Quick Ratio is 9.16, while the Cash Ratio is 8.52.
Transactions by insiders
Recent insider trading involved RA CAPITAL MANAGEMENT, L.P., Director, that happened on Oct 29 ’25 when 0.25 million shares were sold. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Oct 28 ’25 to sell 0.12 million shares. Meanwhile, Director RA CAPITAL MANAGEMENT, L.P. sold 24579.0 shares on Oct 30 ’25.
